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Abstract
RUNX2 is an essential transcription factor required for skeletal development and cartilage formation. Haploinsufficiency of
RUNX2 leads to cleidocranial displaysia (CCD) a skeletal disorder characterised by gross dysgenesis of bones particularly
those derived from intramembranous bone formation. A notable feature of the RUNX2 protein is the polyglutamine and
polyalanine (23Q/17A) domain coded by a repeat sequence. Since none of the known mutations causing CCD characterised
to date map in the glutamine repeat region, we hypothesised that Q-repeat mutations may be related to a more subtle
bone phenotype. We screened subjects derived from four normal populations for Q-repeat variants. A total of 22 subjects
were identified who were heterozygous for a wild type allele and a Q-repeat variant allele: (15Q, 16Q, 18Q and 30Q).
Although not every subject had data for all measures, Q-repeat variants had a significant deficit in BMD with an average
decrease of 0.7SD measured over 12 BMD-related parameters (p = 0.005). Femoral neck BMD was measured in all subjects
(20.6SD, p = 0.0007). The transactivation function of RUNX2 was determined for 16Q and 30Q alleles using a reporter gene
assay. 16Q and 30Q alleles displayed significantly lower transactivation function compared to wild type (23Q). Our analysis
has identified novel Q-repeat mutations that occur at a collective frequency of about 0.4%. These mutations significantly
alter BMD and display impaired transactivation function, introducing a new class of functionally relevant RUNX2 mutants.
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Introduction
Osteoporosis is the major metabolic bone disease among
developed nations. The disease is characterized by low bone
density and reduced bone quality through the deterioration of
bone micro architecture. As a consequence, sufferers have
impaired skeletal strength and an increased susceptibility to
osteoporotic fractures. Bone mineral density (BMD) is a complex
trait and is controlled by environmental and genetic factors [1].
BMD is a primary predictor of osteoporotic fractures; it is however
a continuous trait related to age and weight. Osteoporosis as a
category is a truncation of this continuous normally distributed
trait, defined by a BMD value less than 2.5 SD from the
population mean of young adults [2]. The proportion of fractures
attributable to osteoporosis ranges from 10%–44% [3].
RUNX2 is a key regulator of skeletogenesis, bone and cartilage
formation [4–8] and has been genetically associated with BMD
[9–15]. RUNX2 transactivates genes such as osteocalcin, type 1
collagen and osteopontin and is initially expressed in mesenchymal
condensations where it plays an essential role in osteoblast
differentiation and in chondrocyte maturation [16]. RUNX2
deficient mice have un-mineralized skeletons with few immature
osteoblasts and an absence of vascular and mesenchymal cell
invasion in the cartilaginous templates. Heterozygous mutations in
coding and promoter sequences of RUNX2 cause the dominantly
inherited skeletal syndrome cleidocranial dysplasia (CCD). The
disorder is characterised by persistently open or delayed closure of
sutures, hypoplasia/aplasia of clavicles, Wormian bones, supernu-
merary teeth, short stature and other skeletal abnormalities
[17,18]. A spectrum of severity of CCD symptoms is correlated
with the extent of transcriptional activity remaining in the cognate
mutant RUNX2 with severest symptoms associated with complete
loss of RUNX2 function [19] and milder symptoms correlated
with some residual RUNX2 transactivation function [20].
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RUNX2 has consecutive polyglutamine and polyalanine repeats
(Q/A repeat) in the protein sequence. Such repeat regions have
the capacity to mutate via strand slippage during DNA replication.
Glutamine repeat sequence expansion has been the cause of some
diseases that show genetic anticipation, where severity increases in
subsequent generations as repeat length increases due to errors in
replication [21]. Wild type human RUNX2 contains a 23Q/17A
repeat; 23 consecutive glutamine followed by 17 alanine residues.
An insertion of the polyalanine tract (23Q/27A) was observed in
one patient with CCD [7] although no further polyalanine-related
CCD patients have been reported and no evidence currently
associates the Q-repeat region with CCD. We previously identified
Q-variants (15Q, 16Q, 24Q and 30Q) in an Australian fracture
cohort [9] and two 16Q variants as well as a single alanine
expansion variant (23Q/23A) in a randomly selected population
from Aberdeen [10]. Pineda et al. [22] observed three Q-variants
(16Q, 18Q and 30Q) in a Spanish population. Evidence exists that
the RUNX2 Q-repeat is a site of functional variation; in
carnivores the length of the Q repeat is significantly associated
with mid-face length and nose curvature [23], indicating an effect
on bone growth rates. Sears et al. [24] confirmed the functional
nature of carnivore related Q/A repeat alterations, showing
correlation of transcriptional variation with facial length in
carnivores. These lines of evidence suggest that RUNX2 repeat
variation may be functionally different in the human population.
We hypothesised that glutamine repeat variants would exist in
normal populations and may influence adult BMD and/or risk of
fracture.
Materials and Methods
Study Subjects
The study subjects were obtained from four different epidemi-
ological studies of bone density and are summarised in Table 1. All
subjects were female. Voting in elections in Australia is compul-
sory and each region maintains an electoral roll. The West
Australian study [25] consisted of females between the ages of 70
and 85 years who were randomly ascertained from the electoral
role and approached by letter. The Geelong Osteoporosis study
comprised a cohort recruited at random from the electoral role
(GOS random) [26] and a specific fracture study (GOS fracture),
where all fracture cases over the age of 35 years presenting at the
only two radiology practices in the region were invited to join, as
described [27]. Genotype was obtained on 834 subjects with no
history of fracture from the random sample of GOS and 578 of the
GOS fracture cases. The Sydney study comprised monozygotic
and dizygotic twins who volunteered for studies of general medical
issues through the Australian twin registry, as described [28]. Self
reported history of fracture was available among a series of
questionnaires completed by volunteers. Data were obtained on
980 participants. In the Tasmanian older adult cohort (TASOAC)
study, 388 DNA of females were available of which 385 yielded
genotype data. In this study, subjects ranged from 50 to 80 and
were recruited by random ascertainment from the electoral roll
[29]. For the Aberdeen study, subjects were postmenopausal
women aged between 45 and 55 years who were approached at
random using Community Health Index records of Aberdeen,
Scotland as previously described [30]. Data were obtained on 991
study participants. In addition, 101 elderly female clinic patients
with established osteoporosis and at least one osteoporotic fracture
were available from the Geelong endocrine clinic. A similar cohort
of 200 clinical patients with established osteoporosis defined by
recurrent vertebral fracture was available from a New Zealand
study, as described [31,32]. BMD data were not available for clinic
patients. Individuals in all studies were female Caucasians and no
subjects were excluded. Appropriate written consent was obtained
from subjects under procedures in accordance with the Declara-
tion of Helsinki approved by the relevant human research ethics
committees (HREC) as previously described [25–32]. The
committees are as follows: Sir Charles Gairdner Hospital HREC,
Barwon Health HREC, Northern Sydney Local Health District
HREC, Southern Tasmanian Health and Medical HREC and
University of Otago HREC.
Bone measures
Bone density was measured by dual energy X-ray absorptiom-
etry (DEXA). In the Aberdeen study a Norland XR26 or XR36
was used (Norland Corporation, Fort Atkinson, WI, USA). A
Lunar DPX-L machine was used for the GOS. The Western
Australian study used a Hologic 4500A fan beam densitometer to
measure total BMD of the hip region. A Lunar Achilles ultrasound
machine was used to measure the left calcaneus bone. Measures of
speed of sound (SOS), broadband ultrasound attenuation (BUA)
and bone stiffness were available. In the Sydney study, a Hologic
4500A fan beam densitometer was used to measure BMD at the
lumbar spine, total hip, femoral neck and whole body. Western
Australian, TASOAC and Sydney studies used the same type of
densitometer and were calibrated with the same standard
phantoms.
Detection of Q-variants
PCR was used to amplify RUNX2 exon 1 fragments harboring
the Q/A repeat using the primers forward 59-CCGGCAAAAT-
GAGCGACG-39 and reverse 59-GGGCGGTGTAGCCTCT-
TACCTT-39. The PCRs were carried out in 20 ml reactions
containing 561027 M primers, PCR reaction buffer, 125 mM
dNTPs, 80 ng genomic DNA, 0.5 units Taq polymerase in 20 ml as
specified by the supplier (Promega, Sydney, Australia). The study
populations were genotyped separately by differing means: testing
100 random DNA by all methods gave the same genotypes. For
the GOS and TASOAC, the resulting 336 bp fragments were
resolved via nondenaturing 10% polyacrylamide gel electropho-
resis (PAGE). Heteroduplex analysis was used to determine the
presence of Q-repeat variants. For the Aberdeen populations the
PCR fragment was digested with MspA1I (New England Biolabs)
and resolved on 3% agarose. For the Western Australian samples,
all PCR products were initially analysed via dHPLC (Varian
Prostar 430, Varian Industries, Sydney, Australia) and subse-
quently by heteroduplex PAGE. Genotyping was done twice for all
samples and all variant genotypes confirmed by PAGE to reveal
heteroduplexes. All PCR amplified DNA fragments that displayed
unique mobility patterns on PAGE were sequenced using BigDye
Table 1. Characteristics of population studies.
Study
Age
range
N
genotyped
Recruitment
via Reference
Western Australian 70–82 1078 Electoral roll 25
GOS random 20–92 822 Electoral roll 26
GOS fracture 35–95 598 Present with
fracture
27
Sydney 19–78 980 Twin registry 28
TASOAC 50–80 385 Electoral roll 29
Aberdeen 45–55 991 Health records 30
doi:10.1371/journal.pone.0042617.t001
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Terminator v1.1 ready mix according to the manufacturer’s
protocol (Applied Biosystems).
Plasmids, transfection and cell culture
Expression plasmids containing mutant Q/A domains were
constructed by cloning the XbaI-XbaI fragment from full length
RUNX2 expression plasmid pEF-aA [33] into pUC18 to create
pUC18RUNX2 which served as a template to create glutamine
variants via PCR cloning. PCR was used to amplify partial
RUNX2 promoter and exon 1 fragments from DNA samples
harboring Q/A mutations using the oligonucleotide primers
59-TTCACCACCGGACTCCAACT-39 for the 59 side and 59-
CATCTGGTACCTCTCCGAGGGCTACCACCTTGAAGG-
CCACGGGCAGGGTC-39 for the 39 side. The reverse primer
contained an EcoNI tag facilitating the cloning of the PCR
amplified product into the BglII-EcoNI site of pUC18RUNX2.
Mutant Q/A regions were confirmed by DNA sequencing and the
XbaI-XbaI fragments were cloned into the XbaI-XbaI site of the
mammalian expression vector pEF-BOS [34]. Restriction digest
analysis and DNA sequencing confirmed the orientations of
RUNX2 inserts. pGL3-Basic served as a template to create the
reporter constructs. BglII and HindIII sites were introduced by
PCR amplification in the human osteocalcin gene using oligonu-
cleotide primers 59-CAGGAGATCTCTGACCGTCGAGCTG-39
for the 59 side and 59-GGGCAAGCTTGGTGTCTCGGGTGG-
C-39 for the 39 side. The resulting BglII-HindIII fragment was cloned
into the corresponding sites of pGL3-Basic to create pOSLUC, which
has 590 basepairs of the human osteocalcin promoter, including 70
base pairs of the untranslated message. Oligonucleotides containing a
consensus mouse osteocalcin RUNX2 response element (RRE: 59-
GATCCGCTGCAATCACCAACCACAGCA, with RUNX2 con-
sensus binding site underlined) were cloned into the BglII site of
pOSLUC to create pRRE, which had three copies of the RRE
inserted as direct repeats. Transfections were performed using
FuGENE (Roche) as the manufacturer’s protocols. Antibody
immuno-staining was performed as described in Yoshida et al.
[35]. 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) was kept in the dark
under argon in isopropanol and added with appropriate vehicle
controls after dilution in ethanol. No more than 0.1 ml ethanol per ml
medium was present in cell culture. Western blots of transfected cells
were done by standard methods using anti-RUNX2 antibody (D130-
3, MBL International) according to the manufacturer’s instructions.
Luciferase Assay
NIH3T3 cells and HEK293 cells were maintained in DMEM
(Gibco) supplemented with 10% FBS (v/v) (Gibco), 1% Penicillin-
Streptomycin (v/v) (Gibco) in a 5% CO2 humidified atmosphere
at 37uC. For the luciferase assay NIH3T3 cells were seeded into 6-
well plates at a density of 16105 cells/well 24 hours prior to
transfection. HEK293 cells were seeded into 12-well plates at a
density of 16105 cells/well 24 hours prior to transfection.
NIH3T3 and HEK293 cells were transfected using FuGENE6
transfection reagent according to the manufacturer’s instructions
(Promega). Cells were harvested 48 hours post-transfection.
Luciferase activities were determined using the dual luciferase
assay system described by Dyer et al. 2000 [36]. pRL-CMV
(Promega) was used as an internal control to normalize results.
Gel shift assays, in vitro protein translation and GST pull-
down assays
Gel shift assays were done by standard methods as previously
described, using 5% PAGE and in vitro translated proteins [37].
DNA probes representing RUNX2 binding sites were end labelled
using a fill in reaction of 59 overhangs using DNA polymerase 1
Klenow fragment and fragments purified by PAGE. In vitro
translated human RUNX2 variant proteins 23Q wild type, 16Q-
variant, and 30Q-variant were generated from DNA fragments
representing 23Q, 16Q, or 30Q variants recloned into a T7
promoter containing hRUNX2 vector by using T7 RNA
polymerase (TNTH Promega, USA) and coupled transcription-
translation reactions containing [35S]-methionine. Protein prod-
ucts were visualised and quantified by [35S]-methionine incorpo-
ration. Bacterial over-expression of glutathione-S-transferase
coupled human VDR (GSThVDR) fusion protein was performed
by induction with isopropyl-b-D-thio-galactopyranoside (IPTG,
1.25 mM) for 3 h at 30uC in the JM109 E.coli strain as described
previously [37]. GST pull-down assays were performed by
incubation of GSThVDR with either [35S]-23Q RUNX2 wild
type, [35S]-16Q variant, [35S]-30Q variant RUNX2. As a binding
agent, a GSThVDR-Sepharose bead slurry (50% w/v of beads) in
PPI buffer (20 mM HEPES, pH 7.9; 200 mM KCl; 1 mM
EDTA, 4 mM MgCl2, 1 mM dithiothreitol, 0.1% Nonidet P-40
and 10% glycerol) was used. GST fusion-Sepharose slurries were
pre-blocked in PPI buffer containing bovine serum albumin (1 mg/
ml) prior to use in pull-down assays. Unbound [35S]-23Q RUNX2
wild type, [35S]-16Q variant or [35S]-30Q variant RUNX2
labelled proteins were washed away with PPI buffer. In vitro
translated [35S] 23Q, [35S] 16Q or [35S] 30Q that had bound to
GSThVDR-Sepharose was released from the Sepharose, electro-
phoresed through a 12% SDS-PAGE, and detected by autoradi-
ography using either phosphor screens (BioRad) or X-ray film.
Densitometric analysis on resolved bands was performed using the
ChemicDoc system (BioRad).
Statistical methods
Within studies, Q-variants were analysed using analysis of
variance (ANOVA) and Student’s T-test. Genotype status (Q-
variant carrier or not) was coded as one and zero, respectively, and
used as a variable in ANCOVA analysis to test the effect of
covariates such as age and weight. Age, age-weight and age-
weight21 adjusted values of bone density parameters were
produced using linear regression. Stiffness was loge transformed
to comply with equality of variance assumptions in ANOVA.
These adjustments had no material influence on the conclusions
and Z scores of age-weight21 regression are presented. Incident
fracture during five years of observation was available for the
Western Australian study. Incident fracture was categorised as
zero and one for absence and presence of fracture, respectively, for
analysis by logistic regression and the number of such fracture
events also examined in genotype groups using contingency tables.
Results of logistic regression are presented as p values and odds
ratios (OR) with 95% confidence intervals (CI). Genotypes were
examined pooled (all variants) and separately as either deletions or
insertions. The only measure in common across all studies was
femoral neck BMD. In order to pool all studies, each individual
was expressed within a study as a Z-score of residual femoral neck
BMD from the age-weight21 regression specific for that study.
Under the null hypothesis of no effect at this locus on BMD, the Z
scores should be distributed randomly around a mean of zero.
Population simulations were constructed in excel, using the Monte
Carlo simulation plugin, PopTools [38], and the correlated
variable tool to simulate bone density parameters as a series of
correlated normal distributions, based on the correlations observed
in the populations studied. Results of transfections were analysed
using ANOVA with Fisher’s least significant difference test for pair
wise comparisons. Counts of cells were analysed using contingency
Q Variants in Human RUNX2
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tables and Chi-square. Analysis of covariance was used to analyse
categorical and continuous covariates.
Results
Q-variants identified
From the 1078 individuals genotyped in the Western Australian
study, there were five 16Q alleles, one 18Q allele and two 30Q
alleles. In the GOS random population sample three Q-variants
were identified in 822 subjects: these were one 15Q and two 16Q
variants. In the GOS fracture study, where recruitment was based
on any fracture at any age, four Q-variants were identified in 598
subjects: these were two 16Q and two 30Q variants. In a prior
publication [9], three of these variants were reported (two 16Q
and one 30Q): in this study more samples from the GOS fracture
cohort were genotyped and an additional variant identified. In the
Sydney population of 980, five individuals with Q-variants were
identified: carrying 16Q, 18Q and 30Q. The 16Q and 18Q
variants were found in two pairs of monozygotic twins. The 30Q
variant was in one individual of a dizygotic twin pair. For analysis,
the average bone density values of the monozygotic twin pairs
were taken and the pair considered as a single genetically unique
individual. In the Tasmanian study (TASOAC) no Q-variants
were found in 385 genotyped. In the Aberdeen study, two 16Q
variants were identified previously from 991 subjects [10]; in this
study their bone parameters are reported. In order to estimate the
frequency of the Q-variants without bias, only those populations
where the recruitment strategy involved volunteers were consid-
ered (Western Australia, Geelong, Tasmania and Aberdeen). In
this case, 13 Q-variants were observed within 3276 subjects,
yielding a population frequency estimate of 0.004 (95%CI, 0.002
to 0.007). Using the binomial theorem and the observed frequency
of Q-variants, it is estimated that 95% of repeat studies of a similar
size (approximately 3000 subjects) will detect between 6 and 19
such Q-variant carriers, if allele frequency is similar in other
populations. In 103 female post-menopausal clinic patients with
established osteoporosis with fracture, 16Q and 30Q variants were
found. In a similar population of vertebral fracture cases from New
Zealand [31,32], two 30Q variants were found in 200 patients
genotyped. Therefore, in clinic patients with osteoporosis, four Q-
variants were found in 303 patients genotyped. Apart from those
Q-variants described above, three examples of 24Q alleles were
detected overall. These 24Q subjects were not considered in this
analysis. All Q-repeat variants were heterozygous carriers with the
other chromosome containing a 23Q/17A wild type allele.
Bone density in Q-variants
Characteristics of Q-variant carriers with respect to femoral
neck (FN) Z scores are presented in Table 2. Figure 1 shows the
mean Z score of Q-variants for each measured parameter in each
study cohort. The Q-variant carriers in Western Australian were
compared to non carriers (N = 1021) for differences in the
ultrasound measures of bone density: broadband ultrasound
attenuation (BUA) and speed of sound (SOS). Q-variants had
significantly lower BUA measures (n = 8, BUA, p = 0.025) at the
calcaneus, with a difference of 20.80 standard deviations (SD, or
Z score) and significantly lower SOS (p = 0.05) and log stiffness
(p = 0.013). Weight, height and age were not significantly different
in Q-variants. For all BMD values, age and age-weight21
adjustment was done using regression and adjusted values
produced. Individual values were then expressed as Z scores
around the relevant population mean. While the particulars of
reported measures change depending on such adjustment, the
general outcomes reported here are not dependent on this
mathematical adjustment. Measures of bone density using DEXA
were similarly lower in Q-variants (Fig. 1A) although only
nominally significant with the total hip BMD measure
(p = 0.028). At other sites there was a trend for Q-variants to
have lower BMD compared with all others in the study: femoral
neck (p = 0.22), trochanter (p = 0.065), and intertrochanteric
region (p = 0.06). Of the seven Q-variants identified from GOS
there was a trend for negative Z scores (BMD below the
population mean value, Fig. 1A) with 6 of 7 sites having negative
average BMD. The Q-variant subjects from the Aberdeen study
had negative Z-scores for both femoral neck and lumbar spine
BMD (averaging 21.39SD and 21.36SD, p = 0.01 and p = 0.11
respectively, Fig. 1A). In the Sydney study, the data from each
monozygotic twin pair were averaged and thus three were
available with BMD data. The Q-variants had negative BMD
Z-scores for the femoral neck with an average effect of 20.62SD.
There was a trend for negative Z scores for all bone measures
(Table 3).
Combining BMD data using Monte Carlo simulation
Bone density measures at different anatomical sites are
correlated: additional measures in individuals therefore contribute
useful information to explore the bone phenotype of Q-variants.
All these data from skeletal sites can be used collectively to explore
the genotype-phenotype relationship. Empirical p values based on
Monte Carlo modelling make use of the additional data available
in bone studies, where the scanning methods provide BMD
measures of multiple sites. Considering only Z scores derived from
within each study eliminates the effect of using different DEXA
devices. A simulation was made based on the likelihood of
sampling such individuals with measurements of correlated bone
related variables. Correlated variables were simulated based on the
measured correlations of bone parameters in the various
populations, and a simulation of sampling was done in order to
determine how many such samples met or exceeded the observed
data. This approach was first taken with the Western Australian
study, considering just deletion variants. There were six deletion
variants, identified in a population sample of 1078 subjects, each
with seven measured parameters related to bone. In this case, of
100,000 simulations of sampling six individuals measured for seven
correlated bone parameters, only 252 such samples had an overall
group mean equal to or more negative than the observed mean of
20.74 Z scores for all variables. This yields an empirical
multivariate p value of 0.0025. The GOS study came from a
similar population via similar recruitment with seven bone related
parameters measured; although the bone parameters were
measured using different equipment. The three deletions observed
in GOS study were combined with those from Western Australia
and a simulation done based on the idea of sampling from the
combined population: in this case the observed mean was 20.63 Z
scores and 235 samples from 100,000 trials met or exceeded the
observed mean, giving an empirical p value of 0.0024. When 30Q
variants were combined with all other variants from the two
Australian studies the Monte Carlo based multivariate p value
was: 0.0007. Of the 75 bone related measures from the Q variants
identified in Aberdeen, Western Australia and Geelong studies, 59
measures had negative Z score values. Combining data from the
three studies for Monte Carlo simulation resulted in 9 samples in
100,000 trials; giving an empirical probability of p = 0.0009. These
simulations suggest that the additional measures provide useful
data supporting the hypothesis that Q-variant carriers have lower
bone density and that the average deficit is of the order of 0.7 Z
scores of age, weight21 adjusted BMD.
Q Variants in Human RUNX2
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Using BMD data from the Q-variants derived from the GOS
fracture cohort is not necessary, since a significant p value was
already obtained using data from studies with no apparent
recruitment bias. However, if the GOS fracture and Sydney
cohort data were used in the Monte Carlo simulations the result
was still significant. Addition of all subjects for whom BMD data
were available to the Monte Carlo simulation supported the
hypothesis that Q-variant carriers have significantly lower BMD (3
samples in one million trials with mean values equal to or more
extreme than the observed means).
Femoral neck BMD was the only measure in common between
the GOS random sample, GOS fracture, Aberdeen, Sydney and
Western Australian studies. In order to combine the effects of these
studies, age-weight21 adjusted Z-scores for each study were taken
giving a mean Z score of 20.60. Simply combining all
populations, as if there were one global population from which
the samples were drawn, gave a p value of 0.0007. The conclusions
were not altered appreciably by taking the average of those who
were twins.
Relationship to fracture
In the GOS study, the random sample that was genotyped
excluded any with history of fracture, whereas in the Western
Australian study, although recruitment was essentially random,
fracture was not a reason for exclusion. Of the eight Q-variants
found in the Western Australian study, four had prior osteoporosis
related fractures (hip, spine and arm fractures). Data on incident
fracture during a five year observation period were available for
those who had completed the follow-up. Incident fracture during
the study period was coded as 0 or 1 for absence and presence of
fracture and the type of fracture was ignored. Four of 8 Q-variant
carriers sustained incident fracture whereas the fracture rate was
17.8% in 1036 subjects with the normal 23Q RUNX2 allele. Q-
variant carriers were significantly more likely (Fisher’s exact test,
Figure 1. Characterization of RUNX2 Q variants with respect to clinical measures of bone density and in vitro transactivation. A.
RUNX2 Q-variant carriers from Western Australia, Geelong (GOS random sample and GOS fracture), Sydney and Aberdeen studies have lower mean
bone density parameters. Q-variants have lower mean Z-scores of bone density measured by calcaneal ultrasound (BUA, SOS, Stiff) and by DEXA at
various skeletal sites. Abbreviations: Abd., Aberdeen; BUA, broadband ultrasound attenuation; SOS, speed of sound; Stiff, bone stiffness; FN, femoral
neck BMD; TR, trochanteric region BMD; Hip, Hip BMD; TB, total body BMD; LS, lumbar spine BMD; WT, Ward’s triangle BMD; DR, distal radius BMD;
UD, ultradistal radius BMD. Error bars are standard error. Z-scores presented are the within-study age-weight21 adjusted Z score derived from within
that cohort. B and C. Q-variant expression vectors have diminished capacity to transactivate target promoters in NIH3T3 mouse fibroblasts (B) and
human embryonic kidney cell (HEK293) (C). Cells were transfected as described in the methods. In B the target was pRRE which is the human
osteocalcin promoter with three additional synthetic mouse RUNX2 target sites added upstream, and in C the target promoter construct was 590 bp
of the authentic human osteocalcin promoter driving luciferase (pOSLUC). D. Transfected cells show appropriate sizes of expressed product and
exhibit equivalent amount of protein. NIH3T3 cells were transfected with empty vector (Con) or expression constructs as indicated. Cellular extracts
were Western blotted after electrophoresis on SDS-PAGE. Numbers indicate molecular weight markers in kilodaltons. In B and C transactivation is
expressed as percentage relative to the 23Q variant in order to normalise scales of NIH3T3 and HEK293 cells.
doi:10.1371/journal.pone.0042617.g001
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p = 0.036) to be in the fracture category (OR 4.7 with 95% CI 1.2
to 19.2). Overall, 6 of 8 Q-variants from the Western Australian
study had prior or incident fractures. If the Geelong fracture study
(n = 598) is combined with Western Australian study subjects who
had ever fractured (n = 426), 1024 Australian subjects are available
who had sustained fracture. Combining Western Australian [25]
and GOS [39] subjects who had not reported fracture gave 1478
Australian non-fracture subjects. Despite the fact that no age
matching was done, there was a significant increase (p = 0.036) in
Q-variants within the fracture category in this comparison.
Overall, of 22 Q-repeat variants identified, 12 had sustained
some form of bone fracture, including the clinically important sites
of femur, hip, spine and arm. Within the 30Q variants, three of
five had fractured.
Reduced capacity to transactivate RUNX2 target genes
Expression vectors were constructed to express 23Q, 16Q and
30Q variants of RUNX2. Significantly lower transactivation of
target gene promoters occurred after transfection for 16Q and
30Q compared to the wild type 23Q was observed using a semi-
synthetic RUNX2 reporter construct (pRRE) in mouse fibroblastic
NIH3T3 cells (p = 0.002 and 0.016, for 16Q and 30Q, respec-
tively, Fig. 1B). Similar data was obtained using the human
osteocalcin promoter driving luciferase (pOSLUC) in HEK293
cells (Fig. 1C). Western blot of total protein from transfected
NIH3T3 cells demonstrated the expected differences in apparent
molecular weight in PAGE while there was no evidence a
difference in relative abundance of Q-variants compared to 23Q
wild type. Control cells transfected with empty vector showed no
immunoreactivity (Fig. 1D).
Comparison with CCD-related RUNX2 mutants
CCD is a disease where severe inactivating mutations of RUNX2
exist. Some CCD-related RUNX2 mutants have no transactiva-
tion capacity while others, related to milder phenotypes, have a
residual activity. CBFB is a heterodimer binding partner of
RUNX2, known to increase DNA binding. The ability of RUNX2
variants to co-localise with endogenous CBFB in either nuclear,
and/or cytoplasmic compartments was assessed by confocal
immunomicroscopy with simultaneous staining with RUNX2
and CBFB with different fluorophores (Fig. 2 A–C). Cells were
counted with exclusively nuclear staining, nuclear plus cytoplasmic
and cytoplasmic only staining. The data were expressed as
percentages of cells counted with a particular type of staining. For
RUNX2, more cells with cytoplasmic staining were observed in
transfected cells with 16Q and 30Q variants than expected
compared with wild type 23Q (p = 0.007), with the 30Q having the
stronger effect (p = 0.01). The majority (90%) of cells transfected
with wild type 23Q RUNX2 also showed nuclear localization of
CBFB: the other 10% represented cells with both nuclear and
cytoplasmic staining. For transfected 16Q variant, 75% of positive
cells showed nuclear RUNX2 while only 45% showed nuclear
CBFB (p = 7.561025) with the difference appearing in the
combined nuclear and cytoplasmic compartment (Fig. 2C). For
transfected 30Q, the difference in CBFB binding was not as great:
64% showed nuclear RUNX2 while 54% of cells were also being
positive for nuclear CBFB (p = 0.002) with a 10% increase in the
nuclear and cytoplasmic compartment for CBFB.
The transactivation functions of the Q-variants were analysed
using a third RUNX2 target gene reporter assay and activity
compared to RUNX2 mutants known to cause CCD. Using the
mouse osteocalcin reporter (p147) in NIH3T3 mouse fibroblastic
cells: 16Q and 30Q variants had reduced capacity to transactivate
Table 2. Characteristics of Q-variant allele carriers.
Allele Age Weight Height Z-FN
15Q 41 69 159 20.33
16Q 30 79 171 21.42
16Q 45 56 166 0.07
16Q 47 68 174 21.52
16Q 49 66 161 21.07
16Q* 69 71 165 20.15
16Q 70 56 152 20.34
16Q 72 80 168 0.89
16Q 75 71 165 21.69
16Q 76 52 156 20.91
16Q 78 61 152 20.70
16Q 79 65 167 20.31
16Q 85 70 147 20.13
18Q* 65 66 161 20.21
18Q 74 69 156 20.24
30Q 39 97 161 21.34
30Q 48 62 160 21.37
30Q 72 57 161 0.07
30Q 74 54 162 20.02
30Q 87 50 155 21.18
Age (years), weight (kg), height (cm) and Z-score of femoral neck BMD are
presented. Subjects are ranked by allele length and then age.
*indicates average of identical twin pair. In addition, a 16Q and three 30Q
variants were observed in clinic patients.
doi:10.1371/journal.pone.0042617.t002
Table 3. Bone parameters in standardized Z scores averaged
over all Q-variants carriers.
Site Mean Z N P value
Z_Spine 20.709 14* 0.0032
Z_FN 20.601 22* 0.0006
Z_WT 20.484 6 0.1449
Z_TR 20.774 14* 0.0022
Z_UD 20.102 5 0.8358
Z_MI 20.271 5 0.4149
Z_TB 20.531 10* 0.0844
Z_INT 20.760 7 0.0206
Z_HIP 20.653 11* 0.0146
BUA 20.798 8 0.0254
SOS 20.700 8 0.0505
STIFF 20.809 8 0.0130
N is the number of observations available.
*Asterisk indicates sites with data from more than one study combined using Z
scores. P value is the test of the hypothesis that the mean Z score is zero. Key:
Z_ indicates a Z score adjusted by age weight21 regression, FN is femoral neck,
WT is Ward’s triangle, TR is trochanteric region, UD is ultra distal radius, MI is
Mid shaft of the radius, TB is total body, INT is intertrochanteric region, HIP is
total hip, BUA is broadband ultrasound attenuation measured at the calcaneus,
SOS is speed of sound, STIFF is stiffness and p value refers to loge transformed
stiffness.
doi:10.1371/journal.pone.0042617.t003
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and this was a stronger effect than had been observed in the prior
reporter-cell line combinations (Fig. 2D). The depressed transacti-
vation ability of the 30Q variant was approximately the same as
that observed in the Q266X CCD mutant, whereas the 16Q
variant was similar to that seen in the A348fs mutant. Exogenous
transfected CBFB enhanced wild type RUNX2 activity and
rescued, to a large extent, the transactivation activity on the p147
target promoters when Q-variants were considered (Fig. 2E).
Under the same conditions, the activity of CCD-related RUNX2
mutants was not rescued fully by co-transfection of CBFB partner
(Fig. 2E).
Endogenous CBFB nuclear translocation was significantly
related to RUNX2 Q-variants when observed using confocal
microscopy (Fig. 2 A–C). Despite the fact that endogenous CBFB
localization might be altered in RUNX2 variants, we reasoned
that transfection of CBFB expression vector, may alter the
phenotype of the Q-variants by augmenting endogenous CBFB
levels. Expression vector for CBFB was transfected with Q-variants
and activity on the p147 target in NIH3T3 cells examined.
Vitamin D receptor (VDR) and Q variants
In order to test the interaction of VDR with RUNX2 Q-
variants in cells, the human osteocalcin promoter luciferase
construct (pOSLUC) was transfected into NIH3T3 fibroblasts,
with or without VDR expression vector and with or without
1,25(OH)2D3 and RUNX2 expression vector (Fig. 3A). Differences
in target promoter activity were once again observed, as described
above, with 16Q and 30Q showing significantly lower activity
compared to wildtype 23Q (Fig. 3A). As expected, transfection of
VDR resulted in induction of pOSLUC. In the presence of 45 ng
RUNX2 vector, 10 ng VDR vector and 1,25(OH)2D3 (at 10
28 M)
approximately 63 fold induction of the target vector occurred
compared to empty vector vehicle treated cells (Fig. 3A). In the
absence of 1,25(OH)2D3, transfected VDR had no significant
effect on promoter activity. Treatment of cells with 1,25(OH)2D3,
in the absence of transfected VDR, resulted in some induction of
pOSLUC, consistent with activation of endogenous VDR.
Induction by 1,25(OH)2D3 was increased in the presence of
transfected VDR (p = 1.7610210). In the absence of 1,25(OH)2D3,
both 16Q and 30Q variants had significantly lower target gene
Figure 2. RUNX2 Q-variants have reduced nuclear localization and transactivation activity. A. Expression constructs were transfected
into NIH3T3 cells and RUNX2 detected using confocal immunofluorescence, counts were then made of the number of cells with staining in the
nuclear or cytoplasmic compartment, or both. The figures show representative cells and the insert percentage numbers indicates the proportion of
cells that show that particular staining location. Panel A shows Q-variant forms of RUNX2 and panel B shows RUNX2 mutants that are associated with
the condition cleidocranial dysplasia (CCD). C. Nuclear or cytoplasmic localization of CBFB in cells transfected with RUNX2 Q-variant constructs. D.
RUNX2 Q-variants compared with CCD-associated RUNX2 mutants, tested against the p147 mouse osteocalcin construct. In this assay Q-variants 16Q
and 30Q have a deficit of transcriptional activity that overlaps that of CCD-associated variants. E. Co-transfection of CBFB expression vector with
RUNX2 Q-variants completely overcomes the defect in transcriptional activity detected by the p147 promoter. In contrast, the transcriptional activity
of CCD-associated RUNX2 mutants on the p147 construct is not rescued by CBFB co-transfection. The transcriptional activities of 16Q and 30Q alleles
were compared to wild type 23Q RUNX2 and known CCD-related mutants using an in vitro target gene reporter assay consisting of the proximal
mouse osteocalcin promoter (p147) driving luciferase target gene construct and transfected with expression vector for RUNX2 variants in mouse
NIH3T3 fibroblast-like cells. In D and E, transactivation data are not percentages relative to 23Q wild type, but arbitrary units related to the ratio of
firefly luciferase to Renilla luciferase. Key to symbols: Con, control cells with target gene promoter p147 but transfected with empty expression vector;
23Q, wild type; 16Q and 30Q, Q variants; R211Q, missense mutation at residue 211; Q266X, early termination at residue 266; A348fs, frames shift
mutation at alanine residue 348.
doi:10.1371/journal.pone.0042617.g002
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promoter activity compared to 23Q wild type construct (23Q
versus 16Q, p = 1.161025; 23Q versus 30Q, p = 4.061026),
regardless of the presence or not of transfected VDR. In contrast,
in the presence of 1,25(OH)2D3 and transfected VDR the
difference between 23Q and other Q-variant constructs measured
by osteocalcin promoter activity was eliminated or reduced (23Q
versus 16Q, p = 0.95; 23Q versus 30Q, p = 0.08).
VDR is a RUNX2 partner protein that can be activated by
ligand, 1,25(OH)2D3. To examine the interaction of VDR and
RUNX2 variants, in vitro translated proteins were made and tested
in glutathione-S transferase (GST) pull down reactions for
differences in protein-protein interaction. Unlabelled GST-VDR
fusion construct was used to pull down 35S labelled Q variant
RUNX2 proteins (Fig. 3B). Under these conditions, GST-VDR
demonstrated a strong interaction with RUNX2 (approximately
25% of label being recovered in pull down) but no significant
difference in capacity to pull down RUNX2 Q-variants (p = 0.08),
suggesting that protein-protein interactions of RUNX2 and VDR
are unaffected by either variation in the glutamine repeat or the
GST moiety added to VDR. There was no difference in the
Figure 3. RUNX2 Q-variant interaction with the vitamin receptor (VDR). A. Transfected VDR, activated by 1,25(OH)2D3, can overcome the
deficit in Q-variant transcriptional activity on a target human osteocalcin promoter. Although 16Q and 30Q variants show significantly reduced
transactivation in NIH3T3 cells, as seen previously, transfected VDR alone does not alter the significant defect, however activation of VDR by the
natural ligand 1,25(OH)2D3, results in essentially no difference in activation on the target gene promoter between the Q-variants. Promoter activity
refers to human osteocalcin promoter construct driving fire fly luciferase (pOSLUC). Transactivation units are arbitrary based on the ratio of fire fly to
Renilla luciferase. Empty vector controls are not shown but had activity of about one half unit on this graph. B. There was no detectable difference in
the affinity of [35S] RUNX2 Q-variants for binding labelled VDR protein in in vitro pull-down assays where VDR was used to pull down 35S labelled
RUNX2 protein via an affinity column. C. The ability of in vitro translated RUNX2 Q-variants to bind a RUNX2 DNA element from the mouse
osteocalcin promoter (known as ORE) is enhanced by VDR in a ligand dependant manner. DNA binding was measured by phosphor analysis of
labelled bands in gel shift assays after 5% PAGE. A difference in binding capacity existed on this element. Although addition of VDR or VDR and
1,25(OH)2D3, resulted in a increased total binding, in a ligand dependent manner, there was still a difference in Q-variants relative to 23Q. D. Images
show gel shift data, with triplicates, RUNX2 variants indicated on the image and above the additional proteins added. Data suggest a difference in
DNA binding and interaction with VDR. 1,25D3 in figure indicates 1,25(OH)2D3.
doi:10.1371/journal.pone.0042617.g003
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amount of GST-pull down signal in the presence or absence of
1,25(OH)2D3 ligand.
Quantitative gel-shift assays were done using in vitro translated
RUNX2 variants and a synthetic RUNX2 element from the
mouse osteocalcin gene. These data showed a significant difference
in the binding capacity of the Q-variants to the response element,
suggesting that variation in the Q repeat can influence DNA
binding, at least on some elements. In vitro conditions for ligand
(1,25(OH)2D3) dependent VDR binding to DNA were previously
described [36]. Under these conditions, the RUNX2 response
element binding activity was increased by addition of in vitro
translated VDR protein and further enhanced by addition of
1,25(OH)2D3. Despite increased DNA affinity in the presence of
VDR and 1,25(OH)2D3 a significant difference in the in vitro DNA
binding activity of Q-variants persisted such that 16Q and 30Q
variants were less active than 23Q wild type (Fig. 3 C, D).
Discussion
Various lines of evidence suggest that the RUNX2 Q/A repeat
region has functional polymorphism. We screened samples from
various studies for Q-repeat mutations in RUNX2. A total of 26
Q-variant carriers were identified, involving 24 genetically unique
individuals. The Q-variants did not present with cleidocranial
dysplasia (CCD) and thus we hypothesized that the Q-variants
may alter another skeletal phenotype such as BMD. Overall, Q-
variants were significantly lower for BMD measures including
bone ultrasound attenuation of the calcaneus, and DEXA
measures of BMD at several sites. After pooling BMD measures
from all studies, using Z scores, an overall estimate of the effect of
Q-variant status was obtained. The genetic effect of Q-variants
was around 0.7 Z-score (SD) reduction in bone density whether
measured by DEXA or ultrasound. These data confirm that the
Q-tract of RUNX2 has a reasonably high rate of population
variation and furthermore, suggest that this variation manifests in
the phenotype of lower BMD. Q-variant heterozygotes were
detected at around 0.4%, or around 40,000 per ten million
inhabitants. Q-variant homozygotes are expected to be infrequent;
but such homozygotes may have a more severe phenotype with a
mean effect of 21.4 Z-scores, if the genetic effect is additive.
Whether Q-insertions have a more extreme phenotype than
deletions, as suggested by the BMD data, remains to be
determined in larger populations.
New repeat variants can occur through strand slippage during
replication of repeat sequences such as that encoding the RUNX2
Q-repeat. Expansion of Q-repeats is known in other diseases such
as Kennedy’s disease where expanded androgen receptor repeats
result in motor neuron disease [40] and, incidentally, the length of
the repeat has been related to transcriptional function [41]. Long
Q-repeats are thought to adopt b-sheet structures [42] that coil
into a nanotube by forming a super helix with a critical point of
increased stability at a length of 30Q [43]. This might suggest that
the super structure of the Q-repeat, rather than the length, is
important for altered function. Although the Q-variants observed
in this study were either 30Q or less, it seems possible that longer
repeat expansion of RUNX2 may be observed and may be
associated with some other pathology. Interestingly, the most
frequent variants observed are 16Q and 30Q, each being 7 amino
acids difference from the standard wild type 23Q allele. This
represents a deletion or expansion of 21 base pairs in the DNA
helix, being exactly two turns of the helix increase or decrease,
given the accepted value of 10.5 base pairs per helical turn in
DNA.
The transcriptional activities of the 16Q and 30Q mutants were
analysed using three different luciferase reporter gene assays. The
variants exhibited transactivation function, however at significant-
ly reduced levels compared to wild type (23Q). The effect was of
greater magnitude using a truncated mouse osteocalcin promoter,
p147, where 16Q and 30Q variant activity overlapped that of
some RUNX2 mutations that are associated with cleidocranial
dysplasia. The reduction in transactivation function is consistent
with the decrease in BMD observed. In the case of a heterozygote
with a normal wild-type allele, the net effect would be expected to
reflect the activity of individual alleles. The significant effect of Q-
variant RUNX2 on transactivation activity in transfection assays
could result from effects on DNA binding, nuclear residence and
interactions with partner proteins. Nuclear residence of Q-variants
was decreased significantly in transfected cells while quantitative
gel shift assays suggested a difference in binding to consensus DNA
elements. We cannot distinguish between the nuclear import
effects and direct effects on transcriptional machinery, since we did
not examine in vitro transcription. Regardless of the mechanism, it
seems plausible that the quantitative reduction in the transactiva-
tion capacity of RUNX2 is associated with overall decrease in
BMD seen in human carriers. Accumulated over a lifetime, this
may be enough to explain the observed effects on bone density.
On the other hand, only one semi-synthetic and two natural target
genes were tested, so the effect of Q-variants on other genes is not
known. The vitamin D receptor (VDR) is ligand activated, is
known to bind RUNX2 by interaction on the osteocalcin
promoter [44], and has potent direct effects on bone cells. In the
human, but not in mouse, VDR activates osteocalcin through a
vitamin D response element. In this case, partial recovery of the
transactivation potential of the RUNX2 Q-variants on the human
osteocalcin promoter was observed on co-transfection and
activation of VDR with the ligand 1,25(OH)2D3.
Are the Q-variants related to fracture? While it is suggestive that
a significant effect on incident fracture was observed within the
Western Australian study, this outcome should be viewed with
caution due to the small numbers of Q variants. In addition, the
apparent enrichment of Q-variants in post-menopausal clinic
fracture cases (four variants in 303 cases genotyped) should also be
considered with caution. Given the rare nature of these Q-
variants, much larger studies are required to determine the
relationship with fracture with precision. A frequently quoted
proposition is that for every one standard deviation decrease in
BMD, a person increases two fold in liability for fracture. If the
effect on BMD of Q-variants is similar to the measured amount
(0.7SD deficit), we can expect an increase in liability to fracture of
slightly less than two-fold, if the effect of a gene such as RUNX2
on fracture acts solely via BMD. Based on the observed allele
frequency, very large studies indeed (10,000 cases and controls)
would be required for reasonable power test the hypothesis of
association with fracture at 99% confidence for an odds ratio of
around 2. If the hypothetical effect on fracture is greater than that
suggested by BMD differences, then it may be possible to detect an
effect in smaller numbers.
Severe RUNX2 mutations that cause CCD have a more
profound effect in transfection assays, usually abolishing transacti-
vation [6,7,19,20]. Milder phenotypes are associated with
RUNX2 mutants that have some transactivation function. In
some transactivation assays, notably using the p147 mouse
osteocalcin promoter, the 30Q RUNX2 variant resulted in
transactivation in a manner similar to CCD mutant RUNX2
forms (Q266X), suggesting a phenotype similar to CCD in terms
of transfection. The subjects that carry Q-repeat mutations do not
present with CCD, thus the Q-variant proteins transactivate target
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promoters at levels that are high enough to avoid the manifesta-
tions of CCD but at levels that reduce bone density within the
normal range. Alternatively, some other mechanism may keep the
phenotype out of the range of CCD, such as the CBFB or VDR
interactions that were investigated in this study. The transfection
data are consistent with this hypothesis. Our constructs were based
on the RUNX2 protein that starts MRIPV, an isoform that is
expressed off the second promoter of RUNX2. At least in mouse,
and possibly in human, an isoform beginning MASNS is expressed
off the first promoter. We have not tested the effect of Q-variants
within the context of the isoform RUNX2-II, expressed off the first
promoter. In addition, recent evidence suggests that Q-repeat
regions contain an activity similar to a trans-activation domain
[45,46]. Furthermore, RUNX2 Q/A repeat variation is related to
skull shape in carnivores [25,26] suggesting that functional
polymorphism is associated with this repeat: unfortunately no
data on facial characteristics or skull shape was taken from the
subjects presented in this study. It is also notable that the RUNX2
locus shows evidence of intense evolutionary selection in the
comparison between Neanderthal and modern human DNA
sequences [47]. How this relates to functional change remains to
be established. Our data support a role for the Q-repeat in
contributing to transactivation activity, although we have no data
on a biochemical mechanism. It seems reasonable to conclude that
a number of activities are altered to arrive at a change in target
gene transactivation: including nuclear localization, DNA binding
and possibly the activity of the Q-repeat as a transactivation
function. The data suggests lower transcriptional activity of
RUNX2, contributing to lower bone density and possibly flow-
on increased risk of fracture, through reduced transcriptional
activity in osteoblasts.
There are several limitations of this study. No subjects were
rejected from the collections for any reason prior to genotyping
although some DNA failed to amplify for technical reasons.
Recruitment bias was minimised as far as could be done in such
clinical collections and there is no reason to suspect that genetic
stratification might have influenced the outcome, although this
was not formally tested. Similar results were observed in different
locations, although all populations were essentially Caucasian.
Bone phenotype data were derived from different commercial
devices in each population and were compared through the use of
standardized Z scores or Monte Carlo modelling; which should
remove device-related differences. The study was limited to female
Caucasians. The statistical outcome observed was not dependent
on modelling covariates, although adjusted standardized values are
presented. While statistically significant, these outcomes do not
extend to the whole genome level of significance used in genome
scans, although this study was not designed as a genome scan. The
Q-variants observed in this study may be new mutations, although
intergenerational studies are needed to verify this. If these are new
mutants such a mutable locus may not be detected in a whole
genome association study, as new mutations would be sporadically
associated with genetic markers used in genome scans studies such
as haplotype blocks. We have not formally established that these
variants are new mutations, although the range of alleles (15Q,
16Q, 18Q and 30Q) suggests new mutations and these are
compatible with strand slippage models of DNA replication
through repeated sequences. Furthermore, the biochemical data
based on transfections for Q-variants were tested only in 16Q and
30Q types and only within the context of RUNX2-I isoform.
Biochemical effects of Q-variants may be different in the RUNX2-
II isoform, which is more osteoblast specific [48] and has a
differential interaction with CBFB [49] compared to RUNX2-I.
Three different target constructs were tested, with similar results,
although other target promoters may give different results. Finally,
interactions of VDR and RUNX2 were tested in artificial
constructs with a GST moiety, and tested on a single DNA
element, so differences observed may not relate to the situation in
the human and on other promoters.
In conclusion, the lines of evidence presented here suggest that
variation in the glutamine repeat of RUNX2 has functional
consequence. Significantly different phenotypic values for bone
density parameters were observed in individuals heterozygous for
the Q-variants. Significant functional differences were observed in
assays of transcription factor activity on different target gene
promoters. Furthermore, an alteration in both in vitro DNA
binding activity and nuclear residence was observed, suggesting a
number of different cumulative effects might occur with these
variants. A partial correction of the defect in Q-variant
transcriptional activity was observed in studies of interaction with
two nuclear partners, CBFB and VDR, which are candidates for
increasing residence of the RUNX2 variant on DNA. In addition,
due to the large number of potential carriers, this genetic marker
may be of some interest in the clinical setting. Intriguingly,
transfection of the VDR, in the presence of active 1,25(OH)2D3
overcame some of the in vivo defect in RUNX2 Q-variant,
suggesting a possible route for clinical studies of Q-variant carriers
or at least future studies of the bone phenotype of Q-variants
relative to vitamin D status.
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